# Artivion, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Artivion, Inc).

## Overview

Artivion, Inc. makes medical devices and implantable human tissues used in cardiac and vascular surgery, with a particular focus on aortic disease. Its core portfolio includes aortic stent grafts, On-X mechanical heart valves, surgical sealants, and preserved human tissues for implantable use. The company operates through two reportable segments, Medical Devices and Preservation Services, and sells through direct teams in North America and Europe as well as distributors in other regions. Artivion’s business is shaped by regulatory approvals, surgeon adoption, and the ability to commercialize new products and indications across global markets.

## Products & services

• Aortic stent grafts for aortic repair and dissection
• On-X mechanical heart valves and related surgical products
• BioGlue surgical sealants and adhesives
• Preservation services for cardiac and vascular human tissues
• PhotoFix bovine surgical patches and PerClot hemostatic powder

- **Aortic stent grafts** (35%) — Endovascular and hybrid stent graft systems used to treat aortic aneurysms and dissections.
- **On-X products** (23%) — Mechanical heart valves, ascending aortic prostheses, and related surgical accessories.
- **Surgical sealants** (17%) — BioGlue and related adhesive products used to seal tissue during surgery.
- **Preservation services** (23%) — Processing and preservation of cardiac and vascular implantable human tissues.
- **Other products** (2%) — PhotoFix, PerClot, and other smaller product and distribution revenues.

- Aortic stent graft systems for thoracic and abdominal aortic repair
- On-X mechanical aortic and mitral heart valves and AAP prosthesis
- BioGlue surgical adhesive for sealing in cardiac and vascular surgery
- Preservation services for implantable human cardiac and vascular tissues
- PhotoFix bovine surgical patches and other distributed surgical products
- PerClot hemostatic powder supplied under transitional manufacturing agreement

## Customers

Artivion sells primarily to cardiac, vascular, thoracic, and general surgeons who use its products in complex surgical procedures. In the US and Canada, the company markets through a direct sales force to hospitals and other healthcare facilities, while in EMEA it combines direct field teams with distributors and local subsidiaries. In APAC and LATAM, the company relies more heavily on independent distributors and regional sales and clinical support specialists. Demand is driven by surgeon preference, clinical evidence, regulatory clearance, and the need for specialized products in aortic repair and valve replacement.

- **Cardiac and vascular surgeons** (primary) — They buy valves, stent grafts, sealants, and tissues for complex aortic and valve procedures because product performance and clinical support directly affect outcomes.
- **Hospitals and healthcare facilities** (primary) — They purchase through direct sales teams or distributors for use in operating rooms and specialty surgical programs.
- **Healthcare distributors** (secondary) — They buy and resell products in APAC and LATAM where Artivion has less direct commercial infrastructure.
- **Tissue processing and preservation customers** (secondary) — They rely on preserved human tissues for implantable cardiac and vascular procedures and value availability, quality, and logistics.
- **OEM and specialty surgical customers** (emerging) — They use coating services and selected distributed products such as PerClot and PhotoFix for specialized surgical applications.

- Cardiac surgeons buying valves, sealants, and tissue products for open surgery
- Vascular and thoracic surgeons using aortic stent grafts for aneurysm/dissection repair
- Hospitals and healthcare systems purchasing through direct sales or tenders
- Physicians and clinical teams that need training and procedural support
- Distributors in APAC and LATAM that commercialize products in local markets
- OEM customers using pyrolytic carbon coating services and related components

## Geography

Artivion has a global footprint with major operating subsidiaries in the United States and Germany and additional country entities supporting sales and marketing worldwide. The company’s primary facilities are in Kennesaw, Georgia; Austin, Texas; and Hechingen, Germany, which are important for manufacturing, tissue processing, and European commercial operations. Management says revenues increased across all geographies in 2025, with the strongest growth in EMEA and North America, while aortic stent graft revenue remains mostly outside the US. The company’s commercial model is split between direct sales in North America and EMEA and distributor-led execution in APAC and LATAM, which affects pricing, regulatory execution, and working capital needs.

- **North America** (0%) — The filing states North America was a major growth driver, but no revenue share was disclosed.
- **EMEA** (0%) — The filing states EMEA was a major growth driver, but no revenue share was disclosed.
- **APAC** (0%) — APAC is served through distributors and subsidiaries; no revenue share was disclosed.
- **LATAM** (0%) — LATAM is served through distributors and subsidiaries; no revenue share was disclosed.

- North America is a core market for On-X and AMDS commercialization
- EMEA is anchored by the Hechingen, Germany headquarters and direct field teams
- APAC and LATAM are served mainly through independent distributors
- Aortic stent graft revenue is still predominantly generated outside the US
- Primary facilities in Georgia, Texas, and Germany support manufacturing and tissue processing
- Global expansion increases regulatory, compliance, and currency exposure

## Strategy

Artivion’s strategy is centered on four growth areas: new products, new indications, global expansion, and business development. The company is trying to convert its aortic repair pipeline into commercial revenue by bringing acquired and internally developed products to market, including AMDS and the NEXUS family of products. It is also pursuing regulatory approvals and expanded indications, which matter because the business depends on surgeon adoption and the ability to sell in more countries and more procedures. Select acquisitions, licensing, and distribution agreements are part of the model, allowing Artivion to broaden its portfolio without building every product from scratch.

- **Launch and scale new aortic repair products** (short-term) — New products are the main engine for growth and help offset dependence on mature franchises.
- **Expand regulatory approvals and indications** (medium-term) — Broader approvals increase addressable procedures and support penetration in new geographies.
- **Build international commercial infrastructure** (medium-term) — Direct sales and local support improve execution in EMEA and selected emerging markets.
- **Pursue selective M&A and licensing** (long-term) — Acquisitions and partnerships can add products, capabilities, and distribution faster than internal development alone.

- Develop and commercialize next-generation aortic repair products
- Expand indications and obtain regulatory approvals in new markets
- Grow direct international sales territories and commercial infrastructure
- Use acquisitions and licensing to add complementary technologies
- Bring acquired products such as AMDS and NEXUS to the US market
- Maintain clinical support and surgeon education to drive adoption

## Risks

Artivion faces meaningful execution risk because it depends on regulatory approvals, surgeon adoption, and successful commercialization of specialized products. Its international footprint exposes it to foreign exchange volatility, compliance burdens, distributor risk, and local regulatory changes, while the company also notes the need to maintain a productive relationship with its German Works Council. The business is concentrated in On-X products and aortic stent grafts, so clinical competition, changes in treatment patterns such as TAVR, or slower uptake of new indications could affect revenue. The company also disclosed a prior cybersecurity incident that disrupted ERP, manufacturing, order processing, and shipping, highlighting operational and inventory risks in a regulated manufacturing environment.

- **Dependence on On-X product revenue** [high] — A meaningful portion of revenue comes from the On-X valve franchise, so adverse clinical, regulatory, or competitive changes would have outsized impact.
- **Cybersecurity and ERP disruption** [high] — A prior cyber incident temporarily disrupted operations and affected revenue, manufacturing, order processing, and shipping.
- **Regulatory and clinical adoption risk** [high] — Growth depends on approvals, post-approval studies, and surgeon acceptance of new products and indications.
- **Foreign exchange volatility** [medium] — A large share of business is outside the US, so currency moves can distort reported growth and margins.
- **Supply chain and single-source dependency** [high] — Some materials, supplies, services, and products come from single or sole-source suppliers and single facilities.

- Dependence on On-X products creates concentration risk if adoption slows
- Regulatory approval delays can postpone commercialization of new products
- Foreign exchange swings can affect reported revenue and margins
- Cybersecurity incidents can disrupt ERP, manufacturing, and shipping
- International operations increase compliance and distributor-management risk
- Single-source suppliers and single facilities create supply continuity risk
- Competition from larger medtech firms can pressure pricing and market share

## Accounting

Artivion’s revenue mix includes product sales and preservation services, so investors should watch how the company recognizes revenue across direct sales, distributor channels, and service activity. The company also has transitional manufacturing and supply arrangements, such as PerClot under the Baxter TMSA, and these can create timing and classification issues in reported revenue. Preservation services and tissue processing likely involve estimates around deferred preservation costs, inventory, and service-related accruals, which can affect margins and quarter-to-quarter comparability. The prior cybersecurity incident also raises the possibility of unusual charges, inventory scrap, insurance recoveries, and operational disruptions that may not recur evenly across periods.

- **Revenue recognition across products and services** — Can affect quarterly comparability and segment margins
- **Deferred preservation costs** — Can influence Preservation Services profitability
- **Cybersecurity incident-related accounting** — Can distort operating income and cash flow in affected periods
- **Foreign currency translation** — Affects reported revenue growth and operating margins

- Mix of product sales and preservation services affects revenue timing and margin mix
- Distributor and direct sales channels can create different recognition patterns
- Transitional supply agreements may affect revenue classification and timing
- Deferred preservation costs and tissue processing estimates can affect earnings
- Cyber incident-related costs, scrap, and insurance recoveries may distort periods
- Foreign currency translation can affect reported growth versus constant currency

---

*Last updated: 2026-09-24T12:30:03.289911+00:00*